Deferiprone
Deferiprone
CLINICAL USE
Orally administered chelator:Treatment of transfusional iron overload
DOSE IN NORMAL RENAL FUNCTION
25 mg/kg 3 times daily. Maximum 100 mg/kg daily
PHARMACOKINETICS
Molecular weight                           :139.2 %Protein binding                           :No data %Excreted unchanged in urine     : 15 – see Other Information Volume of distribution (L/kg)       :1.55–1.73half-life – normal/ESRD (hrs)      :2–3/Unknown DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Give 50% of dose and monitor <10           : Give 50% of dose and monitor DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min HD                     :Dialysed. Dose as in GFR <10 mL/min HDF/high flux   :Dialysed. Dose as in GFR <10 mL/min CAV/VVHD      :Dialysed. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Deferiprone is hepatically metabolised (>85%) to predominantly glucuronide conjugates (no chelating activity). Deferiprone, the glucuronide conjugates, and deferiprone-complexed iron are cleared principally by the kidney, with 80% of the dose recovered in the urineSide effects include reversible neutropenia, agranulocytosis, musculoskeletal and joint pain, subclinical ototoxicity, plus case reports of systemic vasculitis and fatal SLECan cause subnormal serum zinc levels Reddish-brown discolouration of the urine reported in 40% of thalassaemia patients undergoing deferiprone therapyDeferiprone removed aluminium in vitro from blood samples of 46 patients undergoing chronic haemodialysis. Only patients with serum aluminium concentrations >80 mcg/mL were included. Deferiprone removed the aluminium faster and more effectively from higher molecular weight proteins than desferrioxamine. (Canteros-Piccotto MA, Fernández-Martin JL, Cannata-Ortiz MJ, et al. Effectiveness of deferiprone (L1) releasing the aluminium bound to plasma proteins in chronic renal failure.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home